Biogen Inc (BIIB) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.

Total Revenue Chart for Biogen Inc

Biogen Inc (BIIB) revenue for FY2025 was USD 9.8B, a 1.4% change from FY2024. Biogen Inc's revenue grew from USD 15.1M in 1985 to USD 9.8B in 2025 (64870.9% over 40 years). Earnings per share grew from USD 0.12 in 2000 to USD 20.87 in 2022 (16760.5%). Revenue compound annual growth rate: 5-year CAGR of -6.1%, 10-year CAGR of -0.9%, 20-year CAGR of 9.1%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$30.48B
Implied Share Price
$206.28
Enterprise Value
$37.87B
Revenue (TTM)
$10.03B
EBITDA
$3.36B
Profit Margin
8.32%
Trailing P/E
36.77
Forward P/E
17.09
Price/Book (MRQ)
1.63
Price/Sales (TTM)
3.04
EV/EBITDA
17.70
EV/Revenue
3.78
Dividend Yield
—
Book Value
$127.61
Free Cash Flow (FY2025)
$2.05B
Free Cash Flow Yield
6.73%

Snapshot as of 6th August 2026 — not point-in-time controlled, may lag the live market by a few days.